Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents
Restricted accessOtherFirst published online February, 2017
Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents
LipGYWindeckerSHuberK. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J2014; 35: 3155–3179.
2.
FaxonDPEikelboomJWBergerPB. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost2011; 106: 572–584.
3.
RuffCTGiuglianoRPBraunwaldE. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet2014; 383: 955–962.
4.
SouthworthMRReichmanMEUngerEF. Dabigatran and postmarketing reports of bleeding. N Engl J Med2013; 368: 1272–1274.
5.
QamarABhattDL. Balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol2015; 11: 200–202.
6.
GibsonCMMehranRBodeC. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J2015; 169: 472–478 e5.
7.
The CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med2010; 363: 930–942.
8.
LambertsMGislasonGHOlesenJB. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol2013; 62: 981–989.
9.
SorensenRHansenMLAbildstromSZ. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet2009; 374: 1967–1974.
10.
DewildeWJOirbansTVerheugtFW. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet2013; 381: 1107–1115.
11.
HammCWBassandJPAgewallS. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J2011; 32: 2999–3054.
12.
AndersonJLAdamsCDAntmanEM. American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013; 127: e663–e828.
13.
StegPGJamesSKAtarD. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J2012; 33: 2569–2619.
14.
O’GaraPTKushnerFGAscheimDD. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2013; 127: 529–555.
15.
WiviottSDStegPG. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet2015; 386: 292–302.
16.
FiedlerKAMaengMMehilliJ. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation. The ISAR-TRIPLE Trial. J Am Coll Cardiol2015; 65: 1619–1629.
17.
BhattDL. When is a double better than a TRIPLE? Stenting in patients with atrial fibrillation. J Am Coll Cardiol2015;65:1630–1632.
18.
SabateMCequierAIniguezA. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet2012; 380: 1482–1490.
19.
BhattDL. Examination of new drug-eluting stents–top of the class!Lancet2012; 380: 1453–1455.
20.
PalmeriniTSangiorgiDValgimigliM. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol2015; 65: 1092–1102.
21.
MauriLKereiakesDJYehRW. DAPT Study Investigators.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med2014; 371: 2155–2166.
22.
YehRWKereiakesDJStegPG. DAPT Study Investigators.Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015; 65: 2211–2221.
23.
UdellJABonacaMPColletJP. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J2015; Aug31, e-pub ahead of print.
